Evaluation of the radiosensitizing effect of MEK inhibitor KZ-001 on non-small cell lung cancer cells in vitro

Huang, Gongchao; Zhang, Wenqin; Tian, Hongqi

doi:10.2478/abm-2023-0064

Abstract

Background

Non-small cell lung cancer (NSCLC) has a poor prognosis and usually presents resistance against radiotherapy. MEK inhibitors have been proven to possess a radiosensitization effect. The compound KZ-001 as a particular MEK inhibitor is superior to the listed MEK inhibitor AZD6244.

Objective

To investigate whether KZ-001 could enhance the radiosensitivity of NSCLC cell lines in vitro.

Methods

MTT and colony formation assay were used to evaluate the radiosensitivity effect of KZ-001. Immunofluorescence, cell cycle, apoptosis staining, and western blot experiments were used to explore the radiosensitivity mechanism.

Results

KZ-001 significantly decreased A549 cell viability at 6 Gy and 8 Gy radiation doses and caused the radiosensitivity at 1 Gy, 4 Gy, and 6 Gy in colony formation experiments. The A549 apoptosis ratio induced by irradiation (IR) combined with KZ-001 increased significantly in comparison with that by IR monotherapy (10.57% vs. 6.23%, P = 0.0055). The anti-apoptosis marker Bcl-XL was found downregulated in KZ-001 and IR-treated A549/H460 cells, but apoptosis marker Bax was downregulated in H460. Extracellular regulated protein kinases (ERK1/2) phosphorylation of H460 cells could be blocked both by IR alone and IR combined with KZ-001. IR combined with KZ-001 is able to inhibit ERK activation of A549 cells apparently. KZ-001 increased the proportion of G2 phase in irradiated cells from 21.24% to 32.22%. KZ-001 could also significantly increase the double-strand break damage cell ratio to more than 30% compared to the irradiation alone group.

Conclusions

MEK1/2 inhibitor KZ-001 is a potential radiosensitizer for clinical applications.

References

Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022; 72:7–33.
Search in Google Scholar Back to article
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends – an update. Cancer Epidemiol Biomarkers Prev. 2016; 25:16–27.
Search in Google Scholar Back to article
Tang L, Wei F, Wu Y, He Y, Shi L, Xiong F, et al. Role of metabolism in cancer cell radioresistance and radiosensitization methods. J Exp Clin Cancer Res. 2018; 37:1–15.
Search in Google Scholar Back to article
Rekers NH, Troost EG, Zegers CM, Germeraad WT, Dubois LJ, Lambin P. Stereotactic ablative body radiotherapy combined with immunotherapy: present status and future perspectives. Cancer/Radiothér. 2014; 18:391–5.
Search in Google Scholar Back to article
Zhong Y, Du Y, Yang X, Mo Y, Fan C, Xiong F, et al. Circular RNAs function as ceRNAs to regulate and control human cancer progression. Mol Cancer. 2018; 17:1–11.
Search in Google Scholar Back to article
Jones HA, Hahn SM, Bernhard E, McKenna WG. Ras inhibitors and radiation therapy. Semin Radiat Oncol. 2001; 11:328–337.
Search in Google Scholar Back to article
Chinnaiyan P, Allen GW, Harari PM. Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras. Semin Radiat Oncol. 2006; 16:59–64.
Search in Google Scholar Back to article
Frémin C, Meloche S. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. J Hematol Oncol. 2010; 3:1–11.
Search in Google Scholar Back to article
Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta. 2007; 1773:1213–26.
Search in Google Scholar Back to article
Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009; 15:3050–7.
Search in Google Scholar Back to article
Xia Y, Wang Y, Xue L, Yu D. Radiosensitizing effect of MEK specific inhibitor U0126 on A549 cells and its mechanism. J Radiat Res Radiat Proc. 2014; 32:10–5.
Search in Google Scholar Back to article
Estrada-Bernal A, Chatterjee M, Haque SJ, Yang L, Morgan MA, Kotian S, et al. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways. Cell Cycle. 2015; 14:3713–24.
Search in Google Scholar Back to article
Zhu Z, Tian H. Radiosensitizing effects of novel benzothiadiazole derivatives on KRAS-mutant non-small cell lung cancers. Int J Biomed Eng. 2018; 41:138–47.
Search in Google Scholar Back to article
Cheng Y, Wang X, Xia X, Zhang W, Tian H. A benzoxazole compound as a novel MEK inhibitor for the treatment of RAS/RAF mutant cancer. Int J Cancer. 2019; 145:586–96.
Search in Google Scholar Back to article
Liu G, Pei F, Yang F, Li L, Amin AD, Liu S, et al. Role of autophagy and apoptosis in non-small-cell lung cancer. Int J Mol Sci. 2017; 18:367.
Search in Google Scholar Back to article
Neal RD, Hamilton W, Rogers TK. Lung cancer. BMJ. 2014; 349:g6560. doi: 10.1136/bmj.g6560
Open DOI Search in Google Scholar Back to article
Aviel-Ronen S, Blackhall FH, Shepherd FA, Tsao M-S. K-ras mutations in non-small-cell lung carcinoma: a review. Clin Lung Cancer. 2006; 8:30–8.
Search in Google Scholar Back to article
Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non–small-cell lung cancer. J Clin Oncol. 1999; 17:668–75.
Search in Google Scholar Back to article
Kim C, Giaccone G. MEK inhibitors under development for treatment of non-small-cell lung cancer. Expert Opin Inv Drug. 2018; 27:17–30.
Search in Google Scholar Back to article
Jones GG, Del Río IB, Sari S, Sekerim A, Young LC, Hartig N, et al. SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers. Nat Commun. 2019; 10:1–16.
Search in Google Scholar Back to article
Lu L, Jiang M, Zhu C, He J, Fan S. Amelioration of whole abdominal irradiation-induced intestinal injury in mice with 3, 3′-Diindolylmethane (DIM). Free Radical Biol Med. 2019; 130:244–55.
Search in Google Scholar Back to article